Is it your view that the effectiveness and side effect profiles of different IL-6 inhibitors -- established and soon-to-market -- will reflect a class effect, or do you feel they will be clinically differentiated?

Is it your view that the effectiveness and side effect profiles of different IL-6 inhibitors -- established and soon-to-market -- will reflect a class effect, or do you feel they will be clinically differentiated?

Is it your view that the effectiveness and side effect profiles of different IL-6 inhibitors — established and soon-to-market — will reflect a class effect, or do you feel they will be clinically differentiated?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Daniel Furst, MD

Daniel Furst, MD

Professor of Rheumatology
Carl M. Pearson Chair of Rheumatology
Director of Interventional Therapeutics
University of California, Los Angeles Medical Center for Health Sciences
Los Angeles, CA